Kinetic Modelling of in Vitro Data of PI3K, mTOR1, PTEN Enzymes and On-Target Inhibitors Rapamycin, BEZ235, and LY294002

European Journal of Pharmaceutical Sciences - Netherlands
doi 10.1016/j.ejps.2016.11.008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

BEZ235 Impairs Gastric Cancer Growth by Inhibition of PI3K/mTOR in Vitro and in Vivo

BMC Pharmacology
2010English

Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2008English

Mechanistic Target of Rapamycin Inhibitors: Successes and Challenges as Cancer Therapeutics

2019English

Retraction: Mammalian Target of Rapamycin Inhibitors for Treatment in Tuberous Sclerosis

Korean Journal of Pediatrics
Child HealthPediatricsPerinatology
2013English

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?

Frontiers in Oncology
Cancer ResearchOncology
2018English

Synergistic Effects of Phenylhexyl Isothiocyanate and LY294002 on the PI3K/Akt Signaling Pathway in HL‑60 Cells

Oncology Letters
Cancer ResearchOncology
2017English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica
MedicinePharmacology
2013English

Glycolytic Glioma Cells With Active Glycogen Synthase Are Sensitive to PTEN and Inhibitors of PI3K and Gluconeogenesis

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2005English

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Cancer Research
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy